A Melbourne-based start-up spun out of the Peter MacCallum Cancer Centre has raised $10 million for the further development of its novel cancer immunotherapy that targets solid tumours such as breast and pancreatic cancers.

The Brandon Capital Partners-managed Medical Research Commercialisation Fund led the investment into biotech Currus Biologics, along with university commercialisation fund Uniseed,